| 摘要 |
<p>An agent is disclosed for suppressing the growth of tumour cells in primary liver cancer. It contains doxorubicin-estron as the active substance and lipiodol ultrafluid as the carrier, the latter containing a lyophilised preparation of human alpha foetoprotein. The proposed method of treating primary liver cancer involves the preparation of a solution of the active substance in lipiodol ultrafluid with the addition of alpha foetoprotein.</p> |
